-
Mashup Score: 11Volume 21 Issue 9, September 2021 - 3 year(s) ago
Volume 21 Issue 9, September 2021
Source: www.nature.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Inhibition of CDK4/6 promotes CD8 T-cell memory formation - 3 year(s) ago
CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in mouse and human CD8 T cells during early stages of activation. Mice receiving tumor-specific CD8 T cells treated with CDK4/6 inhibitors displayed increased T cell persistence and immunologic memory. CDK4/6 inhibition upregulated Mxd4, a negative regulator of Myc, in…
Source: Cancer DiscoveryCategories: Latest Headlines, Oncologists1Tweet-
SCI leader Nathanael Gray & colleagues discovered CDK4/6 inhibitor therapy increases the frequency of #CD8 memory precursors and downregulates expression of #MYC target genes, and may augment long-term protective immunity for #cancerpatients. https://t.co/LBqmnzdhnb #CDK4 #CDK6
-
-
Mashup Score: 4MYC protein interactors in gene transcription and cancer - 3 year(s) ago
This Perspective highlights the importance of proteināprotein interactions for the oncogenic functions of MYC and discusses how the MYC protein interactome might be exploited therapeutically.
Source: Nature Reviews CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW Perspective! Linda Z Penn et al highlight the importance of proteināprotein interactions for the oncogenic functions of #MYC and discusses how the MYC #ProteinInteractome might be exploited therapeutically. https://t.co/GsA52Kjw6q @NatresCancer @pmcancercentre @MBPatUofT https://t.co/cV0nxi9bYn
-
-
Mashup Score: 8MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression - 3 year(s) ago
KRAS -mutant colorectal cancers are resistant to therapeutics, presenting a significant problem for ā¼40% of cases. Rapalogs, which inhibit mTORC1 and thus protein synthesis, are significantly less potent in KRAS -mutant colorectal cancer. Using Kras -mutant mouse models and mouse- and patient-derived organoids, we demonstrate that KRAS with G12D mutation fundamentally rewires translation to…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the May issue: MNK inhibition sensitizes #KRAS-mutant #colorectalcancer to #mTORC1 inhibition by reducing eIF4E phosphorylation and c-#MYC expression. @owen_sansom @CRUK_BI @UofGCancerSci https://t.co/maoSH5TVcx https://t.co/CKmrfNLz0Z
-
-
Mashup Score: 1
The optimal workflow to maximize accurate diagnosis of double-hit lymphoma (DHL) remains contentious. Through a comprehensive analysis of MYC and BCL2 structura
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#OncoAlert The impact of #MYC and #BCL2 structural variants in tumors of #DLBCL morphology and mechanisms of false-negative MYC IHC | ā¦@BloodJournalā© | American Society of Hematology ā¦@ASH_hematologyā© #lymsm #hemepath https://t.co/od3Q3fPg9O
-
-
Mashup Score: 0
Where do I get my information from: http://armandoh.org/resourceFacebook:https://www.facebook.com/ArmandoHasudunganSupport me: http://www.patreon.com/armando…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
Loved to share this on #cellcycle! https://t.co/OGS5NL908z #HemeOnc_Topic_Review #HemeOnc_Clinical_Pearls #Oncogene_Activation #RAS #MYC #Tumor_Suppressor_Genes_Inactivation #P53 (#P21 #Mdm2 #CDK #Cyclin) #APC #BRCA #checkpoint #MolecularGenetics @CancerDotNet #MedEd #oncology
-
-
Mashup Score: 9
Scientists at Lund University have discovered how E. coli bacteria target and degrade the well-known oncogene MYC, which is involved in many forms of cancer. The study is now published in Nature Biotechnology.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Bacterial degradation of the #MYC oncogene: A new #cancer treatment strategy? @NatureBiotech https://t.co/awSuMtwV8Z
-
-
Mashup Score: 5MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression - 3 year(s) ago
KRAS-mutant colorectal cancers (CRC) are resistant to therapeutics, presenting a significant problem for ~40% of cases. Rapalogs, which inhibit mTORC1 and thus protein synthesis, are significantly less potent in KRAS-mutant CRC. Using Kras-mutant mouse models and mouse- and patient-derived organoids we demonstrate that KRAS with G12D mutation fundamentally rewires translation to increase both…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Just published #OnlineFirst: MNK inhibition sensitizes #KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-#MYC expression. @owen_sansom @CRUK_BI @UofGCancerSci https://t.co/ovzDQfIbWL https://t.co/HmEayfE9Uo
-
-
Mashup Score: 0The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies - 3 year(s) ago
Deciphering the impact of metabolic intervention on response to anticancer therapy may elucidate a path toward improved clinical responses. Here, we identify amino acidārelated pathways connected to the folate cycle whose activation predicts sensitivity to MYC-targeting therapies in acute myeloid leukemia (AML). We establish that folate restriction and deficiency of the rate-limiting folate cycle…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the December issue: The folate cycle enzyme MTHFR is a critical regulator of cell response to #MYC-targeting therapies. @LabPuissant #Metabolism https://t.co/8dzpJugS5G https://t.co/ELwXaCkGVD
-
-
Mashup Score: 5
Summary: Recently, small-molecule inhibitors of general transcriptional regulators such as BET proteins and the RNA-PolIIāregulating kinase CDK7 have been shown to have efficacy in multiple solid and liquid tumors. An article in this issue of Cancer Discovery identifies a nongenetic mechanism of resistance related to deficiency of folate that leads, via increased S-adenosylhomocysteine and…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the Spotlightā BETs need greens: Folate deficiency and resistance to #MYC targeted therapies, by @LudovicaMarando and Brian Huntly. https://t.co/cD5c5f4z13 https://t.co/HT5QLDE8LU
-
Our September issue, out NOW! With articles on #immunology & #metabolism in #LiverCancer, #mRNAtranslation plasticity in #CancerProgression, #MYC protein interactors, and collective #CancerInvasion. Plus a World View on cancer in gender-diverse people. š https://t.co/GLnMzcw1pR https://t.co/Ri3fn2GZiX